**S. Table 8. Sensitivity analyses for different outcomes among COVID-19 positive patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcome** | **Studies** | **No. of studies (sample size)** | **Proportion (%)** **(95% CI)** | **I2 (95% CI)** |
| **AKI** | Defined criteria for AKI | 32 (n=11,295) | 17.16 (11.00 - 24.36) | 98.75% (98.57 to 98.91) |
| Prospective/Retrospective  | 46 (n=25,030) | 20.32 (14.82 - 26.44) | 99.16% (99.07 to 99.24) |
| Non-China geography | 16 (n=21,107) | 35.32 (28.74 - 42.19) | 98.83% (98.59 to 99.04) |
| Mean/Median age ≥60 y | 32 (n=24,628) | 28.45 (22.82 - 34.45) | 98.89% (98.73 to 99.02) |
| Sample size >175 | 28 (n=27,210) | 18.66 (12.55 - 25.67) | 99.46% (99.40 to 99.52) |
| **KRT** | Defined criteria for AKI | 19 (n=14,199) | 8.11 (3.27 - 14.86) | 98.98% (98.80 to 99.14) |
| Prospective/Retrospective | 28 (n=24,389) | 10.06 (6.30 - 14.58) | 98.87% (98.70 to 99.02)  |
| Non-China geography | 13 (n=24,360) | 11.15 (5.72 - 18.1) | 99.48% (99.39 to 99.56) |
| Mean/Median age ≥60 y | 9 (n=13,860) | 35.48 (24.22 - 47.63) | 99.05% (98.79 to 99.26) |
| Sample size >175 | 16 (n=26,820) | 8.57 (4.30 - 14.11) | 99.45% (99.36 to 99.52) |
| **Mortality** | Defined criteria for AKI | 16 (n=11,613) | 17.06 (6.53 - 31.23) | 99.30% (99.17 to 99.40) |
| Prospective/Retrospective  | 23 (n=17,228) | 19.05 (11.95 - 27.37) | 99.14% (99.01 to 99.26) |
| Non-China geography | 7 (n=13,521) | 28.17 (16.30 - 41.84) | 99.31% (99.11 to 99.46) |
| Mean/Median age ≥60 y | 9 (n=13,860) | 35.48 (24.22 - 47.63) | 99.05% (98.79 to 99.26) |
| Sample size >175 | 13 (n=16,681) | 24.27 (14.3 - 35.89) | 99.49% (99.40 to 99.56) |

p value was <0.0001 for each of these analysis